ALK-Abello A/S's Partner In North America, Merck & Co. (Westpoint, PA), Reports Phase III Data On Investigational Grass Sublingual Allergy Immunotherapy Tablet
Published: Nov 11, 2013
Copenhagen, 2013-11-09 18:36 CET (GLOBE NEWSWIRE) -- ALK's (ALKB:DC / OMX: ALK B / AKABY / AKBLF) partner for North America, Merck (NYSE: MRK) reported that data from a pivotal Phase III clinical trial with its investigational grass sublingual allergy immunotherapy (AIT) tablet were presented at the 2013 annual meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Baltimore, USA during 7-11 November.
Help employers find you! Check out all the jobs and post your resume.